Claims for Patent: 9,296,769

Summary for Patent: 9,296,769

Title:	Tenofovir alafenamide hemifumarate
Abstract:	A hemifumarate form of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]- methoxy]propyl]adenine (tenofovir alafenamide), and antiviral therapy using tenofovir alafenamide hemifumarate (e.g., anti-HIV and anti-HBV therapies).
Inventor(s):	Liu; Dazhan (Edmonton, CA), Shi; Bing (Foster City, CA), Wang; Fang (Foster City, CA), Yu; Richard Hung Chiu (San Francisco, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	14/197,873
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,296,769
Patent Claims:	1. A composition comprising tenofovir alafenamide hemifumarate, wherein the composition comprises less than about 5% by weight of tenofovir alafenamide monofumarate. 2. The composition of claim 1, wherein the composition comprises less than about 1% by weight of tenofovir alafenamide monofumarate. 3. The composition of claim 1, wherein the composition comprises less than about 0.5% by weight of tenofovir alafenamide monofumarate. 4. The composition of claim 1, wherein the ratio of fumaric acid to tenofovir alafenamide in said composition is 0.5.+-.0.1. 5. The composition of claim 1, wherein the ratio of fumaric acid to tenofovir alafenamide in said composition is 0.5.+-.0.01. 6. The composition of claim 1, having an X-ray powder diffraction pattern that comprises 2theta values of 6.9.+-.0.2.degree. and 8.6.+-.0.2.degree.. 7. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable excipient. 8. The pharmaceutical composition of claim 7, further comprising an additional therapeutic agent. 9. The pharmaceutical composition of claim 8, wherein the additional therapeutic agent is selected from the group consisting of human immunodeficiency virus (HIV) protease inhibiting compounds, HIV nonnucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors. 10. A method for treating a human immunodeficiency virus (HIV) infection comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 1. 11. A method for treating an HIV infection comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 7. 12. The method for treating an HIV infection of claim 10, further comprising administering to the subject one or more additional therapeutic agents selected from the group consisting of human immunodeficiency virus (HIV) protease inhibiting compounds, HIV nonnucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors. 13. A method for treating a hepatitis B virus (HBV) infection comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 1. 14. A method for treating an HBV infection comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 7. 15. A method for preparing a pharmaceutical composition comprising combining the composition of claim 1 and a pharmaceutically acceptable excipient to provide the pharmaceutical composition. 16. The method for treating an HIV infection of claim 10, wherein the composition is administered in multiple daily doses. 17. The method for treating an HIV infection of claim 10, wherein the composition is administered in a single daily dose. 18. The method for treating an HBV infection of claim 13, wherein the composition is administered in multiple daily doses. 19. The method for treating an HBV infection of claim 13, wherein the composition is administered in a single daily dose.